INCB-057643
- Generic Name
- INCB-057643
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N3O5S
- CAS Number
- 1820889-23-3
- Unique Ingredient Identifier
- 87TZD0JEBS
- Background
INCB-057643 is under investigation in clinical trial NCT02959437 (Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)).
A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT06941077
- Locations
- 🇺🇸
Celerion, Inc, Tempe, Arizona, United States
A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06619522
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm Overlap SyndromeMyelodysplastic SyndromeMyeloproliferative NeoplasmRelapsed or Refractory Primary MyelofibrosisSecondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)ET (Essential Thrombocythemia)Myelofibrosis
- Interventions
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 231
- Registration Number
- NCT04279847
- Locations
- 🇺🇸
University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
🇪🇸Hospital Clinico Universitario de Salamanca, Salamanca, Spain
🇺🇸University of Alabama At Birmingham, Birmingham, Alabama, United States
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
- Conditions
- Advanced MalignanciesSolid TumorsMetastatic Cancer
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT02959437
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 137
- Registration Number
- NCT02711137
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.